AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.51+6.11 (+5.59%) ▲|ACN264.27+9.71 (+3.81%) ▲|ADBE248.48+2.34 (+0.95%) ▲|AMAT369.40-12.52 (-3.28%) ▼|AMD488.78+4.88 (+1.01%) ▲|AMGN478.48+17.22 (+3.73%) ▲|AMT194.86+7.57 (+4.04%) ▲|AMZN266.03+15.34 (+6.12%) ▲|AVGO325.48-6.65 (-2.00%) ▼|AXP332.59+7.09 (+2.18%) ▲|BA177.00+3.69 (+2.13%) ▲|BAC51.63+1.97 (+3.97%) ▲|BKNG170.97+15.30 (+9.83%) ▲|BLK1,224.37+63.05 (+5.43%) ▲|BMY64.19+2.48 (+4.02%) ▲|BNY152.72+3.41 (+2.28%) ▲|BRK-B579.09+22.02 (+3.95%) ▲|C124.74+2.03 (+1.65%) ▲|CAT591.30-32.64 (-5.23%) ▼|CL98.76+3.14 (+3.28%) ▲|CMCSA24.85+1.18 (+4.99%) ▲|COF206.31-2.40 (-1.15%) ▼|COP136.94-7.46 (-5.17%) ▼|COST1,046.47+27.21 (+2.67%) ▲|CRM227.11+4.91 (+2.21%) ▲|CSCO103.61+0.64 (+0.62%) ▲|CVS79.96-11.45 (-12.53%) ▼|CVX216.96-8.31 (-3.69%) ▼|DE676.50+10.67 (+1.60%) ▲|DHR234.93+4.82 (+2.09%) ▲|DIS118.95+4.77 (+4.18%) ▲|DUK129.59+3.08 (+2.43%) ▲|EMR170.44+4.05 (+2.43%) ▲|FDX329.40+11.38 (+3.58%) ▲|GD364.87-9.63 (-2.57%) ▼|GE329.45+8.78 (+2.74%) ▲|GEV832.83-85.37 (-9.30%) ▼|GILD174.48+7.01 (+4.19%) ▲|GM92.43+4.09 (+4.63%) ▲|GOOG287.30+9.03 (+3.25%) ▲|GOOGL288.93+8.90 (+3.18%) ▲|GS928.00+31.91 (+3.56%) ▲|HD355.44+21.78 (+6.53%) ▲|HON228.47+4.42 (+1.97%) ▲|IBM254.32+4.28 (+1.71%) ▲|INTC58.27-2.28 (-3.77%) ▼|INTU356.64+11.92 (+3.46%) ▲|ISRG482.10+41.35 (+9.38%) ▲|JNJ276.32+10.15 (+3.81%) ▲|JPM352.11+14.13 (+4.18%) ▲|KO95.80+1.00 (+1.05%) ▲|LIN524.74+13.19 (+2.58%) ▲|LLY1,417.99+8.61 (+0.61%) ▲|LMT595.04-43.96 (-6.88%) ▼|LOW229.38+16.00 (+7.50%) ▲|LRCX221.43-9.29 (-4.03%) ▼|MA672.68+25.50 (+3.94%) ▲|MCD280.22+17.18 (+6.53%) ▲|MDLZ67.38+2.26 (+3.47%) ▲|MDT104.96+6.08 (+6.15%) ▲|META630.00+8.97 (+1.44%) ▲|MMM193.95+16.90 (+9.55%) ▲|MO78.01+1.07 (+1.39%) ▲|MRK150.36+5.69 (+3.93%) ▲|MS193.97+7.88 (+4.23%) ▲|MSFT555.80+34.81 (+6.68%) ▲|MU795.23-59.87 (-7.00%) ▼|NEE88.45+4.12 (+4.89%) ▲|NFLX66.39+2.97 (+4.68%) ▲|NKE40.49+2.01 (+5.22%) ▲|NOW108.81-0.35 (-0.32%) ▼|NVDA200.13-6.56 (-3.17%) ▼|ORCL123.73-2.46 (-1.95%) ▼|PEP142.42+5.15 (+3.75%) ▲|PFE30.79+0.79 (+2.63%) ▲|PG167.32+5.26 (+3.25%) ▲|PLTR171.70-3.70 (-2.11%) ▼|PM211.28+3.25 (+1.56%) ▲|QCOM173.19+8.76 (+5.33%) ▲|RTX198.43-5.39 (-2.64%) ▼|SBUX109.70+4.93 (+4.71%) ▲|SCHW93.37+4.09 (+4.58%) ▲|SO93.12-0.63 (-0.67%) ▼|SPG228.50+6.42 (+2.89%) ▲|T21.83+0.44 (+2.06%) ▲|TMO706.16+7.82 (+1.12%) ▲|TMUS159.17+4.76 (+3.08%) ▲|TSLA385.19-13.31 (-3.34%) ▼|TXN311.49-1.00 (-0.32%) ▼|UBER69.87+3.27 (+4.91%) ▲|UNH409.38+4.94 (+1.22%) ▲|UNP308.53+5.10 (+1.68%) ▲|UPS114.31+5.14 (+4.71%) ▲|USB61.03+1.14 (+1.90%) ▲|V436.57+16.15 (+3.84%) ▲|VZ46.17+0.93 (+2.06%) ▲|WFC87.43+1.90 (+2.22%) ▲|WMT129.17+4.31 (+3.45%) ▲|XOM169.27-8.19 (-4.62%) ▼|AAPL349.51+17.61 (+5.31%) ▲|ABBV294.83+8.83 (+3.09%) ▲|ABT115.51+6.11 (+5.59%) ▲|ACN264.27+9.71 (+3.81%) ▲|ADBE248.48+2.34 (+0.95%) ▲|AMAT369.40-12.52 (-3.28%) ▼|AMD488.78+4.88 (+1.01%) ▲|AMGN478.48+17.22 (+3.73%) ▲|AMT194.86+7.57 (+4.04%) ▲|AMZN266.03+15.34 (+6.12%) ▲|AVGO325.48-6.65 (-2.00%) ▼|AXP332.59+7.09 (+2.18%) ▲|BA177.00+3.69 (+2.13%) ▲|BAC51.63+1.97 (+3.97%) ▲|BKNG170.97+15.30 (+9.83%) ▲|BLK1,224.37+63.05 (+5.43%) ▲|BMY64.19+2.48 (+4.02%) ▲|BNY152.72+3.41 (+2.28%) ▲|BRK-B579.09+22.02 (+3.95%) ▲|C124.74+2.03 (+1.65%) ▲|CAT591.30-32.64 (-5.23%) ▼|CL98.76+3.14 (+3.28%) ▲|CMCSA24.85+1.18 (+4.99%) ▲|COF206.31-2.40 (-1.15%) ▼|COP136.94-7.46 (-5.17%) ▼|COST1,046.47+27.21 (+2.67%) ▲|CRM227.11+4.91 (+2.21%) ▲|CSCO103.61+0.64 (+0.62%) ▲|CVS79.96-11.45 (-12.53%) ▼|CVX216.96-8.31 (-3.69%) ▼|DE676.50+10.67 (+1.60%) ▲|DHR234.93+4.82 (+2.09%) ▲|DIS118.95+4.77 (+4.18%) ▲|DUK129.59+3.08 (+2.43%) ▲|EMR170.44+4.05 (+2.43%) ▲|FDX329.40+11.38 (+3.58%) ▲|GD364.87-9.63 (-2.57%) ▼|GE329.45+8.78 (+2.74%) ▲|GEV832.83-85.37 (-9.30%) ▼|GILD174.48+7.01 (+4.19%) ▲|GM92.43+4.09 (+4.63%) ▲|GOOG287.30+9.03 (+3.25%) ▲|GOOGL288.93+8.90 (+3.18%) ▲|GS928.00+31.91 (+3.56%) ▲|HD355.44+21.78 (+6.53%) ▲|HON228.47+4.42 (+1.97%) ▲|IBM254.32+4.28 (+1.71%) ▲|INTC58.27-2.28 (-3.77%) ▼|INTU356.64+11.92 (+3.46%) ▲|ISRG482.10+41.35 (+9.38%) ▲|JNJ276.32+10.15 (+3.81%) ▲|JPM352.11+14.13 (+4.18%) ▲|KO95.80+1.00 (+1.05%) ▲|LIN524.74+13.19 (+2.58%) ▲|LLY1,417.99+8.61 (+0.61%) ▲|LMT595.04-43.96 (-6.88%) ▼|LOW229.38+16.00 (+7.50%) ▲|LRCX221.43-9.29 (-4.03%) ▼|MA672.68+25.50 (+3.94%) ▲|MCD280.22+17.18 (+6.53%) ▲|MDLZ67.38+2.26 (+3.47%) ▲|MDT104.96+6.08 (+6.15%) ▲|META630.00+8.97 (+1.44%) ▲|MMM193.95+16.90 (+9.55%) ▲|MO78.01+1.07 (+1.39%) ▲|MRK150.36+5.69 (+3.93%) ▲|MS193.97+7.88 (+4.23%) ▲|MSFT555.80+34.81 (+6.68%) ▲|MU795.23-59.87 (-7.00%) ▼|NEE88.45+4.12 (+4.89%) ▲|NFLX66.39+2.97 (+4.68%) ▲|NKE40.49+2.01 (+5.22%) ▲|NOW108.81-0.35 (-0.32%) ▼|NVDA200.13-6.56 (-3.17%) ▼|ORCL123.73-2.46 (-1.95%) ▼|PEP142.42+5.15 (+3.75%) ▲|PFE30.79+0.79 (+2.63%) ▲|PG167.32+5.26 (+3.25%) ▲|PLTR171.70-3.70 (-2.11%) ▼|PM211.28+3.25 (+1.56%) ▲|QCOM173.19+8.76 (+5.33%) ▲|RTX198.43-5.39 (-2.64%) ▼|SBUX109.70+4.93 (+4.71%) ▲|SCHW93.37+4.09 (+4.58%) ▲|SO93.12-0.63 (-0.67%) ▼|SPG228.50+6.42 (+2.89%) ▲|T21.83+0.44 (+2.06%) ▲|TMO706.16+7.82 (+1.12%) ▲|TMUS159.17+4.76 (+3.08%) ▲|TSLA385.19-13.31 (-3.34%) ▼|TXN311.49-1.00 (-0.32%) ▼|UBER69.87+3.27 (+4.91%) ▲|UNH409.38+4.94 (+1.22%) ▲|UNP308.53+5.10 (+1.68%) ▲|UPS114.31+5.14 (+4.71%) ▲|USB61.03+1.14 (+1.90%) ▲|V436.57+16.15 (+3.84%) ▲|VZ46.17+0.93 (+2.06%) ▲|WFC87.43+1.90 (+2.22%) ▲|WMT129.17+4.31 (+3.45%) ▲|XOM169.27-8.19 (-4.62%) ▼|
17.4 C
New York
Thursday, November 5, 2026

Tag: Regulatory

newsFORsourcecompanycontentinformationreleases1market

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

SELECT MEDICAL SIGNS AGREEMENT WITH BALLAD HEALTH TO OPERATE JOINT VENTURE CRITICAL ILLNESS RECOVERY HOSPITAL

MECHANICSBURG, Pa., June 27, 2025 /PRNewswire/ -- Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate...

Consumers Energy Announces New Members of the Executive Team

Vice Presidents named to lead Generation Operations, Lean, and Commercial Supply JACKSON, Mich., June 27, 2025 /PRNewswire/ -- Consumers Energy today announced three new executives...

ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM

NOGALES, Ariz., June 27, 2025 (GLOBE NEWSWIRE) -- – Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of Directors has authorized a $2.0 million expansion of the Company’s existing share repurchase program.

VNET Announces Authorization of Share Repurchase Program Up to US$50 Million

BEIJING, June 27, 2025 /PRNewswire/ -- VNET Group, Inc. ("VNET" or the "Company") (Nasdaq: VNET), a leading carrier- and cloud-neutral internet data center services...

Aemetis Biogas Receives CARB Approval for Seven RNG Pathways

Aemetis Biogas Receives CARB Approval for Seven RNG Pathways

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

        

COPPER GIANT ACQUIRES STRATEGIC 53,474 HECTARE LAND PACKAGE IN THE JURASSIC PORPHYRY BELT OF COLOMBIA

The Company also announces mutual conclusion of its At-The-Market (ATM) equity distribution program with Research Capital VANCOUVER, BC, June 27, 2025 /CNW/ - Copper Giant Resources...

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

GOLDEN SHIELD ANNOUNCES CLOSE OF OVER-SUBSCRIBED PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, June 27, 2025 /CNW/ - Golden Shield Resources Inc....

Man Group PLC : Form 8.3 – American Axle & Manufacturing Holdings, Inc.

FORM 8.3

Dimensional Fund Advisors Ltd. : Form 8.3 – AMERICAN AXLE & MFG HOLDINGS – Ordinary Shares

FORM 8.3

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers